With two de­buts and a SPAC, bio­phar­ma notch­es an­oth­er busy week as IPO raise soars past $7B

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Af­ter a slight lull in the IPO mar­ket ear­li­er this month, the in­dus­try re­turned in full force this week by cel­e­brat­ing two new Nas­daq en­trants in ad­di­tion to a SPAC merg­er.

Centes­sa comes in as the biggest win­ner, pulling in a $330 mil­lion haul and pric­ing above its ex­pect­ed range at $20 per share Fri­day. The 10-in-1 hold­ing com­pa­ny marks the fourth-largest IPO raise among biotechs in 2021, com­ing ahead of all debu­tants ex­cept for Sana, Zymer­gen and Re­cur­sion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN